Front-Line Ibrutinib Plus Venetoclax Effective for CLL Irrespective of Patient Age by HMP Global

Marginal Zone Lymphoma: Biology and Treatment by HMP Global

Ruxolitinib-BET Inhibitor Combo Promising for Myelofibrosis by HMP Global

iFCG Regimen Effective for Young, Fit Patients With IGHV-Mutated CLL by HMP Global

In an interview with Oncology Learning Network, Michelle Melisko, MD, University of California San Francisco, and Melissa Bourestom, Dignitana, discussed the background, benefits, and future potential of the DigniCap Scalp Cooling System, which minimizes hair loss from certain chemotherapy treatments in patients with cancer.

Novel ABL1 Kinase Inhibitor Active in Heavily Pretreated CML by HMP Global

Acalabrutinib Alone or in Combination With Obinutuzumab Improves PFS in Treatment-Naïve CLL by HMP Global

Pacritinib Promising for Patients With Myelofibrosis and Severe Thrombocytopenia by HMP Global

Dr Pegram, Associate Director for Clinical Research, Stanford Comprehensive Cancer Institute, Palo Alto, California, spoke with Oncology Learning Network about the basis, findings, and clinical significance of the HER2CLIMB clinical trial examining the use of tucatinib therapy in patients with HER2-positive breast cancer.

Recapping a late-breaking abstract from ASCO 2019, Dr Abou-Alfa discusses POLO Trial, Olaparib to Treat gBRCA-mutated, Metastatic Pancreatic Cancer.Since the recording of this podcast, olaparib has been approved by the FDA as maintenance therapy for gBRCA-mutated metastatic pancreatic cancer as of December 30, 2019.